OncoPharm

View Top 200 Chart

Back to Rankings Page

Science
**OncoPharm**

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Latest Episodes:

Breast Cancer In A Nutshell Jan 12, 2023

Show notes

Broad, big picture overview of breast cancer and its treatment. Ambitious. Do not recommend listening at 1.5x

Mosunetuzumab And Same-day Pegfilgrastim w/ ddAC Jan 05, 2023

Show notes

New Year - New Drug, mosunetuzumab (a CD3-CD20 T-cell engager) is approved for r/r Follicular Lymphoma. And an intriguing retrospective cohort study found a higher rate of neutropenia with same-day pegfilgrastim in patients receiving dose-dense AC. Link: https://doi.org/10.1177/10781552221148116

2022 New Drug Review Dec 29, 2022

Show notes

This gift-giving season, we ask whether we want to Keep, Re-gift, or Return new oncology drugs approved this past year.

Project Renewal: Capecitabine Dec 22, 2022

Show notes

The FDA's pilot program, project renewal, uses capecitabine for its first label makeover. What's new & what are the possible implications of the DPYD warning now in the prescribing information?

ASH 2022 Highlights Dec 16, 2022

Show notes

Thought on: Double Dauno, but they said it better --> (https://open.spotify.com/episode/0eHEl3bUdZdg3mynUiNMG6?si=88cdab4b882e4667) Blinatumumab FTW The end of "the" neutropenic diet?

TILs, Olutasidenib, T-DXd Dec 08, 2022

Show notes

Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice. Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1). A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.

Bad News For Belantamab-Mafodotin And Atezolizumab's Bladder Cancer Indication Dec 01, 2022

Show notes

Recent voluntary withdrawals from the US market of belantamab-mafodotin and atezolizumab's indication for bladder cancer have us weighing (again) the pros & cons of the accelerated approval program. Also, FDA approves the 1st fecal transplant product.

Mirvetuximab Soravtansine Nov 17, 2022

Show notes

A new antibody-drug conjugate is approved for ovarian cancer.

Metastatic NSCLC Updates: Role of CTLA-4 inhibitors? Nov 10, 2022

Show notes

We review the 5-year update of CheckMate 227 and the POSEIDON to generate the hypothesis that CLTA-4 inhibition has a role in PD-L1 negative metastatic NSCLC. CM 227 update: https://pubmed.ncbi.nlm.nih.gov/?term=36223558 POSEIDON: https://pubmed.ncbi.nlm.nih.gov/?term=36327426 Editorial: https://pubmed.ncbi.nlm.nih.gov/?term=36331243

No Room for MABs at the INN Nov 03, 2022

Show notes

The International Nonproprietary Names (INN) unit from WHO decided to drop the -mab suffix from new drug names. Instead, -tug, -bart, -ment, and -mig will be used. We have some thoughts. INN Report: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122354/#

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected